Skip to content

A Placebo-controlled crossover Study on Arousal Level by Consuming Morinaga DARS Chocolate

A Placebo-controlled crossover Study on Arousal Level by Consuming Morinaga DARS Chocolate - A Placebo-controlled crossover Study on Arousal Level by Consuming Morinaga DARS Chocolate

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000046943
Enrollment
20
Registered
2022-03-08
Start date
2022-02-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

healthy Adult

Interventions

Sponsors

MORINAGA & CO., LTD.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Men and women who are between 40 and 65 years of age at the time of obtaining consent to participate in the study. 2) Healthy and free from chronic physical diseases. 3) Those who have received a sufficient explanation of the purpose and content of the study, are capable of consenting, understand it well, and voluntarily volunteer to participate, and can agree to participate in the study in writing. 4) Those who are able to come to the site on the designated measurement day and undergo the measurement. 5) Those who have been approved to participate in the study by the investigator. Translated with www.DeepL.com/Translator (free version)

Exclusion criteria

Exclusion criteria: 1) Those who currently suffer from any disease and are undergoing drug treatment. 2) Those who have or are being treated for memory disorder symptoms such as dementia. 3) Those who have been taking drugs for the purpose of disease treatment in the past month (excluding those who have been taking drugs for headache, menstrual cramps, common cold, etc.) 4) Patients with a history or current illness of serious disorders of the liver, kidney, heart, lungs, blood, etc. 5) Patients with concomitant disease or history of disease in the digestive organs (history that does not affect participation in the study may be accepted at the discretion of the investigator) 6) Patients with severe anemia 7) Patients with food allergies (including previous history) (especially milk and soy) 8) Women: Pregnant, lactating, or planning to become pregnant during the study period. 9) Patients with alcoholism or other mental disorders. 10) Patients who have been treated with hospitalization within the past 6 months or plan to be hospitalized during the study period. 11) Those who have not completed the second dose of the new coronary vaccine. 12) Those who are likely to change their lifestyle during the test period (e.g., working at night, traveling for a long time). 13) Those who are in the habit of continuously consuming functional foods, health foods, or supplements containing the ingredients (polyphenols) of the test foods at present or within the past 3 months, and those who plan to consume them during the study period (excluding those who are in the habit of continuously consuming foods such as tea, coffee, chocolate, and cocoa that do not contain high polyphenol content or have been processed by concentration). 14) Others who are judged by the investigator to be inappropriate for this study. Translated with www.DeepL.com/Translator (free version)

Design outcomes

Primary

MeasureTime frame
Heart rate, autonomic activity, and arousal subjective symptom survey

Countries

Japan

Contacts

Public ContactSadao Mori

MORINAGA & CO., LTD. Health Science and Research Center, R&D institute

s-mori-ab@morinaga.co.jp045-571-6140

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026